unintended consequences that may result from the unselective application of this performance measure.\textsuperscript{7,8} It may be prudent to explore metrics that also assess medication overuse to avoid treating those at higher risk for adverse consequences of therapy.

Kumar Dharmarajan, MD, MBA
Frederick A. Masoudi, MD, MSPH
John A. Spertus, MD, MPH
Shu-Xia Li, PhD
Harlan M. Krumholz, MD, SM

**Author Affiliations:** Division of Cardiology, Columbia University Medical Center, New York, New York (Dharmarajan); Division of Cardiology, University of Colorado Anschutz Medical Campus, Aurora (Masoudi); St Luke’s Mid America Heart Institute/University of Missouri, Kansas City (Spertus); Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, Connecticut (Dharmarajan, Li, Krumholz); Section of Health Policy and Administration, Yale School of Public Health, New Haven, Connecticut (Krumholz); Robert Wood Johnson Clinical Scholars Program and Section of Cardiovascular Medicine, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut (Krumholz).

**Corresponding Author:** Kumar Dharmarajan, MD, MBA, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, 1 Church St, Ste 200, New Haven, CT 06510 (kumar.dharmarajan@yale.edu).

**Published Online:** June 24, 2013. doi:10.1001/jamainternmed.2013.7717.

**Author Contributions:** Drs Dharmarajan, Li, and Krumholz had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Dharmarajan, Krumholz.

**Acquisition of data:** Li, Krumholz.

**Analysis and interpretation of data:** Dharmarajan, Masoudi, Spertus, Li, Krumholz.

**Drafting of the manuscript:** Dharmarajan, Li, Krumholz.

**Critical revision of the manuscript for important intellectual content:** Dharmarajan, Masoudi, Spertus, Krumholz.

**Statistical analysis:** Dharmarajan, Li.

**Obtained funding:** Krumholz.

**Administrative, technical, and material support:** Krumholz.

**Study supervision:** Krumholz.

**Conflict of Interest Disclosures:** Drs Dharmarajan, Li, and Krumholz had no conflicts of interest to disclose.

**Funding/Support:** This project was supported by grant DFI0-301 from the Patrick and Catherine Weldon Donaghy Medical Research Foundation in West Hartford, Connecticut; grant UL1 RR024139-06S1 from the National Center for Advancing Translational Sciences in Bethesda, Maryland; and grant U01 HL105270-02 (Center for Cardiovascular Outcomes Research at Yale University) from the National Heart, Lung, and Blood Institute of the National Institutes of Health. Dr Dharmarajan is supported by grant HL07854 from the National Heart, Lung, and Blood Institute and is also supported as a Centers of Excellence Scholar in Geriatric Medicine at Yale by The John A. Hartford Foundation and the American Federation for Aging Research.

**Role of the Sponsors:** The funding sponsors had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript.


**Editor’s Note**

**Performance Measures: Better Outcomes, Not Better Grades**

Performance measures are widely used with the goal of improving care of patients with heart failure and other illnesses. This study by Dharmarajan et al illustrates that performance measures may sometimes have unintended consequences. The authors show that in the enthusiasm to achieve the measure of placing patients with heart failure on β-blocker therapy at hospital discharge, many patients who should not receive β-blockers are getting them, while others who meet the criteria are not. It is likely that there was more thoughtful discussion and decision making behind these decisions that is not captured in administrative data used for this analysis. However, it must also be remembered that the purpose of performance measures is to improve patient care, not to get high grades. Too much focus on meeting a target can distract us from the care of the whole patient.

Rita F. Redberg, MD, MSc

**Published Online:** June 24, 2013. doi:10.1001/jamainternmed.2013.7769.

**Hepatitis C Virus Screening and Prevalence Among US Veterans in Department of Veterans Affairs Care**

From 2.7 to 3.9 million Americans are living with hepatitis C virus (HCV) infection, and 45% to 85% are unaware they are infected.\textsuperscript{1-4} In August 2012, the Centers for Disease Control and Prevention (CDC) began recommending 1-time HCV screening for persons born from 1945 through 1965 because...